Science (filter)

Anaptys Publications and Relevant Literature

Search results will appear here

Rosnilimab

November, 2024 — American College of Rheumatology (ACR) Convergence 2024

Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis

Ren et al., 2024

October, 2024 — United European Gastroenterology Week (UEGW)

Rosnilimab, a PD-1 Agonist Antibody in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis

Parmley et al., 2024

June, 2024 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting

Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling

Parmley et al., 2024

June, 2024 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting

Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling

Parmley et al., 2024

May, 2024 — Digestive Disease Week (DDW) Annual Meeting

Optimizing PD-1 Agonist Signaling With Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2024

May, 2024 — Digestive Disease Week (DDW) Annual Meeting

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1+ Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial

Luu et al., 2024

February, 2024 — European Crohn’s and Colitis Organisation (ECCO) Congress

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduces T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1^high Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial

Luu et al., 2024

February, 2024 — European Crohn’s and Colitis Organisation (ECCO) Congress

Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2024

November, 2023 — American College of Rheumatology (ACR) Convergence

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial

Luu et al., 2023

November, 2023 — American College of Rheumatology (ACR) Convergence

Optimizing PD-1 Agonist Signaling with Membrane-Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2023

November, 2022 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Demonstrated Modulation of Peripheral T Cell Activity and Reduction of Circulating PD-1 high Expressing CD4 and CD8 T Cells in a Phase 1 Healthy Volunteer Clinical Trial

Dahl et al., 2022

December, 2023 — Nature

PD‑1‑Positive Cells Contribute to the Diagnosis of Inflammatory Bowel Disease and Can Aid in Predicting Response to Vedolizumab

Kim et al., 2023

January, 2023 — Science Immunology

Anti–PD-1 Antibodies Recognizing the Membrane Proximal Region are PD-1 Agonists that can Downregulate Inflammatory Diseases

Suzuki et al., 2023

June, 2020 — International Immunology

PD-1 and PD-1 Ligands: From Discovery to Clinical Application

Okazaki et al., 2020

ANB032

May, 2007 — The Journal of Allergy and Clinical Immunology

Major Differences in Inflammatory Dendritic Cells and Their Products Distinguish Atopic Dermatitis From Psoriasis

March, 2013 — Journal of Investigative Dermatology

Therapeutic Potential of B and T Lymphocyte Attenuator Expressed on CD8⁺ T Cells for Contact Hypersensitivity

Nakagomi et al., 2013

December, 2013 — Immunity

The Inhibitory Receptor B and T Lymphocyte Attenuator Controls γδ T Cell Homeostasis and Inflammatory Responses

Bekiaris et al., 2013

November, 2022 — Cell Reports

BTLA Signaling in Conventional and Regulatory Lymphocytes Coordinately Tempers Humoral Immunity in the Intestinal Mucosa

Stienne et al., 2022

November, 2020 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Discovery and Characterization of ANB032, a Novel BTLA/HVEM Checkpoint Modulator for Autoimmune/Inflammatory Disease

Dahl et al., 2020

November, 2021 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Soluble BTLA (sBTLA) is Induced Following Targeting of BTLA In-vivo by ANB032, a Novel BTLA/HVEM Modulator Therapeutic Antibody for the Treatment of Autoimmune Disease

Dahl et al., 2021

December, 2021 — Antibody Engineering & Therapeutics Conference

ANB032, a Novel BTLA/HVEM Therapeutic Antibody, Inhibited T cells Derived from Atopic Dermatitis Patients In-vitro

Hsu et al., 2021

May, 2023 — International Societies for Investigative Dermatology (ISID) Meeting

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibited T Cell Proliferation, Reduced Inflammatory Cytokines, and Down Modulated BTLA Expression on Circulating T and B Cells in Phase 1, Progresses Into a Phase 2 Study in Atopic Dermatitis

Luu et al., 2023

October, 2023 — European Academy of Dermatology & Venerology (EADV) Congress

A Phase 2b, Randomized, Double Blind, Placebo Controlled, Multicenter, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

Silverberg et al., 2023

October, 2023 — European Academy of Dermatology & Venerology (EADV) Congress

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study

Luu et al., 2023

November, 2023 — 5th Inflammatory Skin Disease Summit (ISDS)

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study

Luu et al., 2023

November, 2023 — 5th Inflammatory Skin Disease Summit (ISDS)

A Phase 2b, Randomized, Double Blind, Placebo Controlled, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Moderate to Severe Atopic Dermatitis

Ehst et al., 2023

February, 2024 - American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells

Luu et al., 2024

March, 2024 — American Academy of Dermatology (AAD) Annual Meeting

ANB032, an Investigational B and T Cell Lymphocyte Attenuator (BTLA) Checkpoint Receptor Agonist, Modulates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology

Muench et al., 2024

ANB033

June, 2023 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases

Hare et al., 2023

Imsidolimab

October, 2007 — Journal of Experimental Medicine

Opposing Activities of Two Novel Members of the IL-1 Ligand Family Regulate Skin Inflammation

Blumberg et al., 2007

February, 2011 — The Journal of Immunology

IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression

Johnston et al., 2011

August, 2011 — The New England Journal of Medicine

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

Marrakchi et al., 2011

September, 2011 — The American Journal of Human Genetics

Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis

Onoufriadis et al., 2011

2012 — Expert Review of Dermatology

IL-36: a Potential Psoriasis Target?

Raison et al., 2012

August, 2012 — Current Opinion in Pharmacology

IL-36 in Psoriasis

Towne et al., 2012

November, 2013 — Journal of Investigative Dermatology

The Majority of Generalized Pustular Psoriasis Without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist

Sugiura et al., 2013

April, 2023 — British Journal of Dermatology

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial

Warren et al., 2023

May, 2018 — European Academy of Allergy and Clinical Immunology (EAACI) Congress

A Phase 1 Study of ANB019, an Anti-Interleukin-36-Receptor (IL-36R) Monoclonal Antibody, in Healthy Volunteers

Khanskaya et al., 2018

October, 2021 — European Academy of Dermatology & Venereology (EADV) Annual Congress

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial

Gudjonsson et al., 2021

September, 2024 — European Academy of Dermatology & Venereology (EADV) Congress

Imsidolimab, an IL-36 Receptor Antagonist, Was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients With Generalized Pustular Psoriasis Results From the Phase 3 Trials, GEMINI-1 and GEMINI-2

Reich et al., 2024

September, 2024 — European Academy of Dermatology & Venereology (EADV) Congress

Imsidolimab, an IL-36 Receptor Antagonist, was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients with Generalized Pustular Psoriasis: Results from the Phase 3 Trials, GEMINI-1 and GEMINI-2

Reich et al., 2024

Immuno-Oncology

July, 2021 — mAbs

Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1 Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal Models

Kumar et al., 2021

2014 — American Association for Cancer Research Annual Meeting

Generation of Antagonistic Anti-TIM-3 and LAG-3 Monoclonal Antibodies for Potential Novel Immunotherapy Combinations

Jun et al., 2014

2014 — American Association for Cancer Research Special Conference on Tumor Immunology and Immunotherapy

Identification and Characterization of a Potent Anti-Human Tim-3 Antagonist

Correia et al., 2014

2015 — Keystone Symposium on Antibodies as Drugs

Generation of Anti-LAG-3 Monoclonal Antibodies for use in Immunotherapy Combinations

Jun et al., 2015

2015 — American Association for Cancer Research Annual Meeting

Targeting PD-1, TIM-3 and LAG-3 in Combination for Improved Immunotherapy Combinations

Kehry et al., 2015

2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics

Discovery of TSR-022, a Novel, Potent Anti-TIM-3 Therapeutic Antibody

Laken et al., 2016

2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics

Identification and Characterization of TSR-042, a Novel Anti-PD-1 Therapeutic Antibody

Laken et al., 2016